Prevalence of mumps antibodies in the Israeli population in relation to mumps vaccination policy and incidence of disease

Epidemiology and Infection

Volumn 136, Issue 5, 2008, Pages 688-693

  Muhsen, Kh ^a,b   Aboudy, Y ^c   Mendelson, E ^c   Green, M S ^a,b   Cohen, D ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^c MINISTRY OF HEALTH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; MUMPS ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; EPIDEMIC; EPIDEMIOLOGICAL DATA; FEMALE; HEALTH CARE POLICY; HEALTH SURVEY; HERD IMMUNITY; HIGH SCHOOL; HUMAN; IMMUNE RESPONSE; INCIDENCE; ISRAEL; MALE; MUMPS; MUMPS VIRUS; PREVALENCE; SERODIAGNOSIS; SOLDIER; TREND STUDY; VACCINATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CROWDING; DISEASE OUTBREAKS; FEMALE; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; INFANT; ISRAEL; MALE; MIDDLE AGED; MUMPS; SEROEPIDEMIOLOGIC STUDIES; SOCIOECONOMIC FACTORS;

EID: 41549128511     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268807008989     Document Type: Article

References (26)

1. Gupta RK, Best J, MacMahon E. Mumps and the UK epidemic 2005. British Medical Journal 2005; 330: 1132-1135.
2. Centers for Disease Control and Prevention (CDC). Mumps epidemic - United kingdom, 2004-2005. Morbidity and Mortality Weekly Report 2006; 55: 173-175.
3. Nussinovitch M, Volovitz B, Varsano I. Complications of mumps requiring hospitalization in children. European Journal of Pediatrics 1995; 154: 732-734.
4. Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: A global review. Bulletin of the World Health Organization 1999; 77: 3-14.
5. van Loon FP, et al. Mumps surveillance - United States, 1988-1993. Morbidity and Mortality Weekly Report. CDC Surveillance Summaries 1995; 44: 1-14.
6. Watson JC, et al. Measles, mumps, and rubella - vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report. Recommendations and Reports 1998; 47 (RR-8): 1-57.
7. Gay N, et al. Mumps surveillance in England and Wales supports introduction of two dose vaccination schedule. Communicable Disease Report. CDR Review 1997; 7: R21-6.
8. Peltola H, et al. Mumps and rubella eliminated from Finland. Journal of the American Medical Association 2000; 284: 2643-2647.
9. Peltola H, et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. New England Journal of Medicine 1994; 331: 1397-1402.
10. Donaghy M, Cameron JC, Friederichs V. Increasing incidence of mumps in Scotland: Options for reducing transmission. Journal of Clinical Virology 2006; 35: 121-129.
11. The Israel Center for Disease Control. Notifiable infectious diseases in Israel - 50 years of surveillance 1951-2001. The Israel Center for Disease Control. Publication no. 224, 2003, pp. 25-27, 37.
12. Slater PE, Anis E, Leventhal A. The control of mumps in Israel. European Journal of Epidemiology 1999; 15: 765-767.
13. Slater PE, Roitman M, Costin C. Mumps incidence in Israel - impact of MMR vaccine. Public Health Reviews 1990; 18: 88-93.
14. The Israel Center for Disease Control. Health Status in Israel 2003, selected health indicators in the general population. Israel Center for Disease Control. Publication number 235a. 2004, pp. 50.
15. Osborne K, Weinberg J, Miller E. The European sero-epidemiology network. Eurosurveillance 1997; 2: 29-31.
16. Tischer A, et al. Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia: Epidemiology and Infection 2007: 1-11. Unpublished online 30 March 2007. doi:10.1017/S0950268807008266.
17. Amela C, Pachon I, de Ory F. Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey. European Journal of Epidemiology 2003; 18: 71-79.
18. Mossong J, Putz L, Schneider F. Seroprevalence of measles, mumps and rubella antibodies in Luxembourg: Results from a national cross-sectional study. Epidemiology and Infection 2004; 132: 11-18.
19. Matter L, et al. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination. European Journal of Epidemiology 1997; 13: 61-66.
20. Anderson RM, May RM. Immunisation and herd immunity. Lancet 1990; 335: 641-645.
21. Fine PE. Community immunity. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia: Elsevier Inc., 2004, pp. 1443-1461.
22. Huerta M, et al. Declining population immunity to mumps among Israeli military recruits. Vaccine 2006; 24: 6300-6303.
23. Backhouse JL, et al. Evaluation of two enzyme immunoassays for detection of immunoglobulin G antibodies to mumps virus. Clinical and Vaccine. Immunology 2006; 13: 764-767.
24. Centers for Disease Control and Prevention (CDC). Update - multistate outbreak of mumps - United States, January 1-May 2, 2006. Morbidity and Mortality Weekly Report 2006; 55: 559-563.
25. Davidkin I, Valle M, Julkunen, I. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up. Vaccine 1995; 13: 1617-1622.
26. Jin L, Beard S, Brown DW. Genetic heterogeneity of mumps virus in the United Kingdom: Identification of two neW genotypes. Journal of Infectious Disease 1999; 180: 829-833.